Co-Diagnostics, Inc. and CoSara Diagnostics to inaugurate new oligo facility

Dec. 17, 2024
New oligonucleotide facility is designed to support "Make in India" initiative by synthesizing Co-Primers in-house. Attendees of new ribbon-cutting event expected to include representatives from NGOs and government leaders.

Co-Diagnostics, Inc. announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

Co-Diagnostics release on PRNewswire

ID 235673643 © Alessandro Biascioli | Dreamstime.com
dreamstime_xxl_235673643
ID 199567781 © Prostockstudio | Dreamstime.com
dreamstime_xxl_199567781
ID 161909343 © Fizkes | Dreamstime.com
dreamstime_xxl_161909343
ID 126044587 © motortion | Dreamstime.com
dreamstime_xxl_126044587
ID 343039477 © Ahmadrizal7373 | Dreamstime.com
dreamstime_xxl_343039477